$13.30
+0.47 (+3.66%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ENTA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
45 interventional · 10 with posted results
Held by 10 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, Qube Research & Technologies Ltd, +5 more) · FINRA short interest 17.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusNCT07482657Time to complete resolution of clinical signs of RSV as measured by RESOLVE-PRandomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: zelicapavir, Placebo | RSV Infection, RSV, Respiratory Syncytial Virus (RSV) | 150 | Dec 2026 | ≤ 134 d | 2026-07-20 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy AdultsNCT07540910Safety measured by adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: EDP-978, Placebo | Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | 98 | Nov 2026 | ≤ 103 d | 2026-04-21 |
| A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.NCT05568706results2026-08-19Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) SymptomsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-938, Placebo | RSV Infection | 187 | 2025-06-23actual | — | 2026-08-19 |
| A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy ParticipantsNCT06917508Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323Open-label · Basic science | Phase 1 | Completed | Drug: EDP-323, Midazolam, Caffeine, Rosuvastatin | RSV Infection, Drug Drug Interaction | 24 | 2025-06-06actual | — | 2025-07-01 |
| A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.NCT06847464Cmax of EDP-323 with and without coadministration with ItraconazoleNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: EDP-323, Itraconazole, EDP-323, carbamazepine, EDP-323, Quinidine, EDP-323, fluconazole | RSV Infection, Drug Drug Interaction (DDI) | 48 | 2025-05-24actual | — | 2025-07-01 |
| A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsNCT06601192Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of ZelicapavirRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin | RSV Infection, QTc Interval | 72 | 2025-02-02actual | — | 2025-07-28 |
| A Study to Evaluate EDP 938 Regimens in Children With RSVNCT04816721results2025-07-08Part 1: Concentrations of EDP-938 in PlasmaRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-938, Placebo | Respiratory Syncytial Virus (RSV) | 99 | 2024-08-19actual | — | 2025-07-28 |
| A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge ModelNCT06170242results2025-10-07Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2, Placebo | RSV Infection | 142 | 2024-06-17actual | — | 2025-10-07 |
| Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractNCT04633187results2024-08-22Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) ComplicationRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to a strategic business decision and not due to safety concerns. | Drug: EDP-938, Placebo | Respiratory Syncytial Virus Infections | 9 | 2023-05-31actual | — | 2024-08-22 |
| A Study of EDP-323 in Healthy SubjectsNCT05587478Safety measured by adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: EDP-323, Placebo | RSV Infection | 82 | 2023-03-29actual | — | 2023-09-01 |
| A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19NCT05616728results2024-08-19Number of Adverse Events as a Measure of Safety and TolerabilityRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-235, Placebo | COVID-19 | 231 | 2023-02-08actual | — | 2024-08-19 |
| Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.NCT05594602Cmax of EDP-235 with and without coadministration with ItraconazoleNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: EDP-235, EDP-235, EDP-235, Itraconazole, Carbamazepine, Quinidine | COVID-19 | 36 | 2022-12-14actual | — | 2023-04-27 |
| Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy SubjectsNCT05594615Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-235Open-label · Treatment | Phase 1 | Completed | Drug: EDP-235, Midazolam, Rosuvastatin, Caffeine | COVID-19 | 24 | 2022-11-04actual | — | 2023-04-27 |
| A Study of EDP-235 in Healthy SubjectsNCT05246878Safety measured by adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: EDP-235, Placebo | SARS CoV 2 Infection | 72 | 2022-07-20actual | — | 2022-08-19 |
| A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult SubjectsNCT04196101results2023-10-30Total Symptom Score (TSS) Area Under the Curve (AUC)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-938, Placebo | Respiratory Syncytial Virus | 82 | 2022-01-04actual | — | 2023-10-30 |
| A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.NCT04971512Safety measured by adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Due to adverse safety signals in Part 1 (HV) | Drug: EDP-721, Placebo (Part 1), EDP-721 (Part 2), Placebo (Part 2), EDP-514, Placebo (Part 2) | Chronic Hepatitis B Virus Infection | 26 | 2021-12-20actual | — | 2022-02-14 |
| A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASHNCT04378010results2023-05-19Proportion of Participants Who Achieve ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis and/or Resolution of Steatohepatitis and no Worsening of Liver Fibrosis as Determined by Liver BiopsyRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Enanta Pharmaceuticals, Inc. made the strategic decision to discontinue the ARGON-2 study to prioritize combination treatment approaches. This decision was not based on safety concerns. | Drug: EDP-305 1.5 mg, EDP-305 2 mg, Placebo | Non-Alcoholic Steatohepatitis | 98 | 2021-10-04actual | — | 2023-05-19 |
| A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on TreatmentNCT04470388Safety measured by adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: EDP-514, Placebo | Chronic HBV Infection | 25 | 2021-08-30actual | — | 2022-01-11 |
| A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)NCT04008004Safety measured by adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: EDP-514, Placebo | Chronic HBV Infection | 99 | 2021-07-14actual | — | 2022-01-11 |
| Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male SubjectsNCT04927793Cmax of EDP-938 in plasmaOpen-label · Basic science | Phase 1 | Completed | Drug: EDP-938 | Respiratory Syncytial Virus (RSV) | 8 | 2021-07-04actual | — | 2022-03-23 |
| Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy SubjectsNCT04783753Cmax of EDP-514 with and without coadministration with itraconazoleNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: EDP-514, EDP-514, EDP-514, Itraconazole, Carbamazepin, Quinidine | Hepatitis B | 72 | 2021-06-28actual | — | 2021-08-16 |
| A Study of EDP-297 in Healthy SubjectsNCT04559126Safety measured by adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: EDP-297, Placebo | NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | 82 | 2021-06-21actual | — | 2021-10-29 |
| Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy SubjectsNCT04498741Cmax of tacrolimus with and without coadministration with EDP-938Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: EDP-938, EDP-938, EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, EDP-938, Midazolam | RSV Infection | 89 | 2021-05-27actual | — | 2021-10-13 |
| Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy SubjectsNCT04871724Cmax of EDP-938 with and without coadministration with fluconazoleOpen-label · Treatment | Phase 1 | Completed | Drug: EDP-938, Fluconazole | RSV Infection | 24 | 2021-03-30actual | — | 2021-05-04 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary CholangitisNCT03394924results2021-05-18Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to BaselineRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-305 1 mg, EDP-305 2.5 mg, Placebo | Primary Biliary Cholangitis | 68 | 2019-12-19actual | — | 2021-05-18 |
| A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge ModelNCT03691623results2022-05-03Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral LoadRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-938 Dose 1, EDP-938 Dose 2, Placebo, EDP-938 Dose 3, EDP-938 Dose 4, Placebo | RSV Infection | 179 | 2019-09-30actual | — | 2022-05-03 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic SteatohepatitisNCT03421431results2021-09-16Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EDP-305 Dose 1, EDP-305 Dose 2, Placebo | Non-Alcoholic Steatohepatitis | 134 | 2019-06-14actual | — | 2021-09-16 |
| A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female SubjectsNCT03783897Area under the plasma concentration-time (AUC0-τ) curve for OC with and without coadministration with EDP-305Open-label · Basic science | Phase 1 | Completed | Drug: EDP-305, Oral Contraceptive | NASH - Nonalcoholic Steatohepatitis | 43 | 2019-06-04actual | — | 2019-07-24 |
| Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy SubjectsNCT03755778Cmax of EDP-938 with and without coadministration with itraconazoleNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: EDP-938, EDP-938, EDP-938, Itraconazole, Rifampin, Quinidine | RSV Infection | 72 | 2019-01-21actual | — | 2019-06-14 |
| Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsNCT03750383Cmax of EDP-938 with and without coadministration with cyclosporineNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: EDP-938, EDP-938, Cyclosporine, Prednisone | RSV Infection | 48 | 2018-11-17actual | — | 2019-02-12 |
| Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male SubjectsNCT03748628Cmax of EDP-305 in plasmaOpen-label · Basic science | Phase 1 | Completed | Drug: EDP-305 | NASH - Nonalcoholic Steatohepatitis | 8 | 2018-10-13actual | — | 2018-11-21 |
| Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy VolunteersNCT03610945Cmax of EDP-305 with and without coadministration with fluconazoleNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Fluconazole, Quinidine, EDP-305, EDP-305 | NASH - Nonalcoholic Steatohepatitis | 48 | 2018-08-15actual | — | 2018-12-05 |
| A Study of EDP-938 in Healthy SubjectsNCT03384823Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: EDP-938, Placebo | RSV Infection | 90 | 2018-07-03actual | — | 2018-10-10 |
| A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersNCT03207425Cmax of EDP 305Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: EDP 305 | NASH | 29 | 2017-09-16actual | — | 2017-11-06 |
| Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy VolunteersNCT03213145Cmax of EDP-305 with and without coadministration with itraconazoleNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: intraconazole, Rifampin, EDP 305 | NASH - Nonalcoholic Steatohepatitis | 48 | 2017-08-10actual | — | 2017-11-06 |
| A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLDNCT02918929Safety data including but not limited to adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urinalysis).Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: EDP 305, Placebo | Presumptive NAFLD | 146 | Jun 2017actual | — | 2017-08-21 |
| Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.NCT03187496Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-305.Open-label · Basic science | Phase 1 | Completed | Drug: Midazolam, Caffeine, Rosuvastatin, EDP-305 | NASH | 24 | 2017-06-01actual | — | 2017-08-21 |
| EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C PatientsNCT02652377Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, and abnormal clinical laboratory results administered to healthy volunteers and multiple doses of EDP-494Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: EDP-494, Placebo | Hepatitis C | 100 | 2016-12-27actual | — | 2017-01-23 |
| Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C SubjectsNCT01856426Change from baseline Hepatitis C viral load at Day 1Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: EDP239, Placebo | Hepatitis C | 28 | Nov 2014actual | — | 2016-01-29 |
| Two-way Interaction Between Alisporivir and EDP239NCT02173574Area Under the Plasma Concentration-time Curve (AUC)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: DEB025, EDP239 | Hepatitis C Virus | 42 | Nov 2014actual | — | 2015-01-09 |
| Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788NCT02255968Incidence and severity of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Terminated | Drug: EDP-788, Placebo | Healthy | 16 | Oct 2014actual | — | 2015-05-12 |
| Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788NCT01999725Incidence and severity of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: EDP-788, Placebo | Safety in Normal Volunteers | 80 | Sep 2014actual | — | 2015-01-09 |
| Multiple Ascending-Dose Study of EDP 322 in Healthy Adult VolunteersNCT00990145The study objective was to determine the safety, tolerability and pharmacokinetics of multiple oral doses of EDP-322 in healthy volunteers.Randomized · Triple-masked | Phase 1 | Completed | Drug: EDP-322 | MRSA, SSTI | 52 | Mar 2009actual | — | 2009-10-08 |
| Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired PneumoniaNCT00270517Clinical Cure 7-14 days after end of therapyRandomized · Double-masked · Treatment | Phase 2 | Unknown status | Drug: EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days | Community Acquired Pneumonia | 250 | — | — | 2006-09-19 |
| Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy VolunteersNCT00989872The study objectives included determining the safety, tolerability and pharmacokinetics of single oral doses of EDP-322 in healthy adult volunteersRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: EDP-322 | Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus | 67 | — | — | 2009-10-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19